Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA

20 Oct 2015

Abstract excerpt

// Marco Perez 1 , Sandra Muñoz-Galván 1 , Manuel P. Jiménez-García 1 , Juan J. Marín 1, 2 , Amancio Carnero 1 1 Instituto de Biomedicina de Sevilla, IBIS/Hospital Universitario Virgen del Rocio/Universidad de Sevilla/Consejo Superior de Investigaciones Cientificas, Seville, Spain 2 Department of Public Health and Preventive Medicine, University of Seville, Seville, Spain Correspondence to: Amancio Carnero,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26528855
DOI: 10.18632/oncotarget.5829

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNAPMID 26528855Read ↗

CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic TargetsSemantic proximity Read ↗

Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumorsSemantic proximity Read ↗

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibitionSemantic proximity Read ↗

Molecular Pathways: CDK4 Inhibitors for Cancer TherapySemantic proximity Read ↗

Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In VivoSemantic proximity Read ↗

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesotheliomaSemantic proximity Read ↗

Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer TreatmentSemantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibitionSemantic proximity Read ↗

CDK4/6 inhibitor: from quiescence to senescenceSemantic proximity Read ↗

Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle PathwaySemantic proximity Read ↗

The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.